Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB

Neuroscientific Biopharmaceuticals — BioShares Conference 2018

13 slides from Neuroscientific Biopharmaceuticals's conference presentation, Jul 31, 2018

  1. Slide 1: NeuroScientific Biopharmaceuticals Ltd

    For personal use only NeuroScientific Biopharmaceuticals Ltd Novel drug therapies for neurodegenerative conditions

  2. Slide 2: Disclaimer

    DISCLAIMER For personal use only 2 The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further

  3. Slide 3: Alzheimer's Disease: The need for novel therapeutics

    3 For personal use only ALZHEIMER’S DISEASE: The need for novel therapeutics Pathology of AD Therapeutics Drug Targets Characterised by two Approved drugs do not Therapeutic pathological hallmarks; stop the progression of approaches targeting Aβ plaques & tau the disease Aβ plaques have yet aggregat

  4. Slide 4: Alzheimer's Disease: Why so many past failures?

    4 For personal use only ALZHEIMER’S DISEASE: Why so many past failures? Pathology of AD Diagnosis of AD Outcomes Measures Disease pathology not Definitive diagnosis Lack of reliable clearly understood of patients in biomarkers Aβ plaques & tau clinical trials Clinical end-points aggregates may not b

  5. Slide 5: Developing a novel compound for the treatment of AD

    5 For personal use only NEUROSCIENTIFIC BIOPHARMACEUTICALS Developing a novel compound for the treatment of AD EmtinB; advanced preclinical lead drug candidate LRP-1 receptor agonist, inducing survival and neurite outgrowth Co-developed by the University of Copenhagen & the University of Tasmania (M

  6. Slide 6: Evolution of EmtinB

    6 For personal use only EVOLUTION OF EMTINB MT-II Structure EmtinB Peptide EmtinB Peptide Dendrimer β-domain α-domain 61 amino acid length 14 amino acid length Synthesised as a Binds divalent metal Isolated from the β- dendrimer: ions domain of MT-II  Increased potency and Difficult to manufacture

  7. Slide 7: EmtinB Mechanism of Action

    EMTINB MECHANISM OF ACTION 7 For personal use only Binding of LRP-1 activates signaling molecules extracellular signal- regulated kinase (ERK), protein kinase B (Akt) and cAMP response element binding protein (CREB) Watch the video on NSB’s website: http://www.neuroscientific.com /research-developme

  8. Slide 8: EmtinB Scientific Data: Preclinical studies

    8 For personal use only EMTINB SCIENTIFIC DATA Preclinical studies Increased mean survival of rate Stimulates neurite of brain cells >90% outgrowth by up to 300% Cell survival: 48-hour incubation period Neurite length: 24-hour treatment period EmtinB 92% EmtinB 225% Induced toxicity 64% Control 100%

  9. Slide 9: EmtinB Scientific Data: Preclinical studies in AD models

    EMTINB SCIENTIFIC DATA 9 For personal use only Preclinical studies in AD models Prevented cell death in in vitro Slowed progression of disease Alzheimer’s model of toxicity (memory impairment) by >80% in Alzheimer’s animal model Control 100% Cognition: treatment for 48 days Aβ-42 50% EmtinB 70% +7 C

  10. Slide 10: Supporting Scientific Data

    SUPPORTING SCIENTIFIC DATA 10 For personal use only Precursor to EmtinB (MT-II) stimulated regenerative growth of optic nerve cells Treatment group (8 rats) all demonstrated 3x regenerative response from single dose 4 weeks post treatment Regeneration of the Optic Nerve (axonal growth) Treatment No

  11. Slide 11: EmtinB Development Schedule

    EMTINB DEVELOPMENT SCHEDULE 11 For personal use only Plan to undertake early-phase clinical studies Q1 2019

  12. Slide 12: Development Pipeline

    DEVELOPMENT PIPELINE 12 For personal use only NSB has a pipeline of potential drug candidates, including 3 other peptides related to EmtinB

  13. Slide 13: Corporate Overview

    CORPORATE OVERVIEW 13 For personal use only Completed IPO listing on the ASX Capital Structure on the 27 July 2018 ASX code NSB Shares on issue 73,580,592 Lead candidate funded through to completion of Phase I Price (close 27/07/2018) $0.225 Market cap $16.5M Pipeline of potential therapeutic Shares

NeuroScientific Biopharmaceuticals — BioShares Conference 2018 on 6ix